

INFINITY PHARMACEUTICALS, INC.
 Form 4/A
 May 08, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Perkins Adelen Q

2. Issuer Name and Ticker or Trading Symbol
 INFINITY PHARMACEUTICALS, INC. [INFI]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 05/03/2007

____ Director
 Officer (give title below) EVP and Chief Business Officer
 ____ 10% Owner
 ____ Other (specify below)

C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)
 05/07/2007

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

CAMBRIDGE, MA 02139

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount (A) or (D) Price | | |
| Common Stock | 05/03/2007 | | P | | 700 A \$ 11.2399 | D | |
| Common Stock | 05/03/2007 | | P | | 200 A \$ 11.2499 | D | |
| Common Stock | 05/04/2007 | | P | | 1,000 A \$ 11 | D | |
| Common Stock | 05/04/2007 | | P | | 1,200 A \$ 11 | D | |
| | 05/04/2007 | | P | | 1,000 A \$ 11.2 | D | |

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4/A

| | | | | | | | |
|--------------|------------|---|-------|---|------------|---------|---|
| Common Stock | | | | | | | |
| Common Stock | 05/04/2007 | P | 1,000 | A | \$ 11.15 | 183,027 | D |
| Common Stock | 05/04/2007 | P | 1,000 | A | \$ 11.05 | 184,027 | D |
| Common Stock | 05/04/2007 | P | 1,000 | A | \$ 11.03 | 185,027 | D |
| Common Stock | 05/04/2007 | P | 1,000 | A | \$ 11.03 | 186,027 | D |
| Common Stock | 05/04/2007 | P | 1,000 | A | \$ 11.025 | 187,027 | D |
| Common Stock | 05/04/2007 | P | 600 | A | \$ 11.2 | 187,627 | D |
| Common Stock | 05/04/2007 | P | 500 | A | \$ 11.2299 | 188,127 | D |
| Common Stock | 05/04/2007 | P | 500 | A | \$ 10.99 | 188,627 | D |
| Common Stock | 05/04/2007 | P | 240 | A | \$ 11.04 | 188,867 | D |
| Common Stock | 05/04/2007 | P | 100 | A | \$ 11.035 | 188,967 | D |
| Common Stock | 05/04/2007 | P | 108 | A | \$ 10.999 | 189,075 | D |
| Common Stock | 05/07/2007 | P | 900 | A | \$ 10.9 | 189,975 | D |
| Common Stock | 05/07/2007 | P | 200 | A | \$ 10.9 | 190,175 | D |
| Common Stock | 05/07/2007 | P | 100 | A | \$ 10.9 | 190,275 | D |
| Common Stock | 05/07/2007 | P | 800 | A | \$ 10.9 | 191,075 | D |
| Common Stock | 05/07/2007 | P | 500 | A | \$ 10.88 | 191,575 | D |
| Common Stock | 05/07/2007 | P | 500 | A | \$ 10.88 | 192,075 | D |
| Common Stock | 05/07/2007 | P | 1,000 | A | \$ 10.88 | 193,075 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Perkins Adelene Q
C/O INFINITY PHARMACEUTICALS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139

EVP and Chief Business Officer

Signatures

/s/ Adelene Q. 05/07/2007
Perkins

**Signature of Date
Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.